NCT02540369

To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.

PEGASUS: A Prospective obsErvational Study in Patients With Wet aGe-related Macular Degeneration or Diabetic Macular Edema to ASsess the Use of Intravitreal Aflibercept in roUtine Clinical practiceS in Canada

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,150 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To describe the use of intravitreal aflibercept in routine clinical practice and to describe follow-up as well as treatment patterns in patients with wAMD or DME in routine clinical practice in Canada for a study population of treatment naive patients and those who have received prior therapy (anti-VEGF injections, laser, steroids, etc).

Conditions

• Wet Macular Degeneration

Interventions

Type	Name	Description
DRUG	Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)	Administration by intravitreal injection.Muti-target Anti-VEGF agent. Dosing would be at physicians discretion.

Timeline

• Start date: 2015-12-14
• Primary completion: 2017-09-25
• Completion: 2018-01-26
• First posted: 2015-09-03
• Last updated: 2019-02-15

Locations

1 site across 1 country: Canada